Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumors 483Solid Tumor 446Advanced Solid Tumor 414Unspecified Adult Solid Tumor, Protocol Specific 362Solid Tumors 336Mesothelioma, Malignant 324Mesothelioma 289Solid Tumor, Adult 124Carcinoma, Non-Small-Cell Lung 122Retinoblastoma 117Lung Neoplasms 77Ovarian Neoplasms 75Melanoma 65Sarcoma 62Carcinoma, Renal Cell 59Stomach Neoplasms 58Pancreatic Neoplasms 58Neoplasms 53Esophageal Neoplasms 53Small Cell Lung Carcinoma 52Colorectal Neoplasms 52Hematopoietic and Lymphatic System Neoplasm 50Uterine Cervical Neoplasms 46Breast Neoplasms 46Solid Tumours 35Neoplasm Metastasis 35Advanced or Metastatic Solid Tumors 35Squamous Cell Carcinoma of Head and Neck 34Carcinoma, Hepatocellular 32Triple Negative Breast Neoplasms 31

Interventions

atezolizumab 1Tiragolumab 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Rare Malignant Solid Neoplasm × Other solid neoplasm × Clear all
NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡